Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 7/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.38 |
| ▸ | STK4 | Q13043 | 1/20 | 0.37 |
| ▸ | STK3 | Q13188 | 1/20 | 0.37 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.37 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.37 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180313 | 0.88 | FGFR1 (0.47) | FGFR1ABL1RIPK2ACVR1LCK | |
| SCHEMBL4192757 | 0.87 | RIPK2 (0.53) | FGFR1ABL1RIPK2ACVR1LCK | |
| SCHEMBL4178720 | 0.85 | FGFR1 (0.47) | FGFR1ABL1RIPK2ACVR1LCK | |
| SCHEMBL4180903 | 0.85 | MAPK14 (0.50) | MAPK14 | |
| SCHEMBL4182714 | 0.81 | FGFR1 (0.48) | FGFR1ABL1LCKMAPK14EGFR | |
| SCHEMBL4176329 | 0.81 | FGFR1 (0.47) | FGFR1ABL1RIPK2LCKMAPK14 | |
| SCHEMBL4180883 | 0.79 | FGFR1 (0.51) | FGFR1ABL1RIPK2EGFRSRC | |
| SCHEMBL4173564 | 0.79 | MAPK14 (0.64) | FGFR1ABL1RIPK2ACVR1LCK | |
| SCHEMBL4186477 | 0.78 | RIPK2 (0.54) | FGFR1ABL1RIPK2ACVR1LCK | |
| SCHEMBL13928692 | 0.77 | WEE1 (0.51) | FGFR1ABL1LCKMAPK14EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | claimed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | IL1B, TPMT, IL1R1 | FGFR1 2037/4885ABL1 3754/4885RIPK2 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.